Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,281 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,281 Papers indexed
1,440 Papers AI scored
39,281 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39281 results
B
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.
PMID 38941509 Published: 2024-06-28 Ingested: 2026-08-02 12:02 AM Cancer
AI -
Standard 79.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 71.0; sample size: 20.0; recency: 80.0; abstract quality: 85.0.

B
Boron Neutron Capture Therapy for High-Grade CNS Tumors: Mechanisms, Carriers, and Clinical Progress: A Narrative Review.
PMID 41898626 Published: 2026-03-18 Ingested: 2026-08-02 12:06 AM International journal of molecular sciences
AI -
Standard 79.69
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 61.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 79.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 85.8; sample size: 50.0; recency: 100.0; abstract quality: 85.0.

B
CK2 inhibitor CX-4945 targets EWS-FLI1 protein abundance and shows anti-tumor activity in metastatic mouse models of Ewing Sarcoma.
PMID 41040216 Published: 2025-09-26 Ingested: 2026-08-02 12:05 AM bioRxiv : the preprint server for biology
AI -
Standard 79.66
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 60.8; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
AI -
Standard 79.64
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 45.7; sample size: 50.0; recency: 100.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 38.2; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 79.64
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 38.2; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
AI -
Standard 79.64
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.6/100. Study design: 80.0; human relevance: 95.0; therapeutic relevance: 68.2; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
Assessment measures for chemotherapy-induced peripheral neuropathy among pediatric oncology patients: an updated systematic review.
PMID 40442349 Published: 2025-05-29 Ingested: 2026-08-02 12:04 AM Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
AI -
Standard 79.64
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 79.6/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 45.7; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 242 of 3274
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic